Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is among the 7 Oversold Pharma Stocks to Buy Now.

Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is among the most oversold stocks.

TheFly reported on February 3 that Lake Street Capital Markets reduced its price target on AQST to $6 from $8 and maintained a Buy rating. This update followed the company’s announcement that it would resubmit its application in the third quarter after receiving a Complete Response Letter for Anaphylm. In order to account for the expected delay in approval, the company revised its revenue forecasts and modified its valuation.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) also revealed on February 20 that it will present new clinical results for its investigational product, Anaphylm (dibutepinephrine) sublingual film, at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, which will take place in Philadelphia from February 27 to March 2. Additional evidence bolstering Anaphylm’s profile as a non-invasive substitute for injectable epinephrine in the treatment of severe allergic responses, including anaphylaxis, will be presented in the presentations.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a specialty pharmaceutical company developing and commercializing orally administered and film-based drug delivery therapies for neurological and other central nervous system disorders.

While we acknowledge the potential of AQST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AQST and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.

Disclosure: None.